TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with 20% sequential growth and a significant net income increase, even considering the nonrecurring tax benefit. The raised revenue guidance and successful share repurchase program further support a positive outlook. Although operating expenses exceeded guidance, the company's strategic investments are expected to pay off. The Q&A section highlights strong demand and market share gains, with conservative guidance suggesting potential upside. Overall, these factors indicate a positive sentiment and likely stock price increase in the short term.
Key Financial Performance
Total global revenue $616 million, with a 92% year-over-year growth. The growth was driven by strong performance of BRIUMVI, particularly in the U.S. market.
BRIUMVI U.S. net sales $594 million, contributing the majority of the total revenue. This reflects a 92% year-over-year growth and 20% sequential growth from Q3 to Q4. Growth was attributed to increasing physician confidence, patient retention, and expanding utilization.
Fourth quarter revenue $183 million for BRIUMVI U.S. net sales, showing a 20% sequential growth from Q3. This growth was driven by new patient starts, prescriber base expansion, and better-than-expected persistence.
Operating expenses $328 million for the full year 2025, slightly above the guidance of $300 million to $320 million. The increase was due to incremental manufacturing and development costs for subcutaneous BRIUMVI and commercial investments.
Net income $447.2 million for the full year 2025, compared to $23.4 million in 2024. This includes a nonrecurring income tax benefit of approximately $340 million, primarily from the release of deferred tax asset valuation allowance.
Share repurchase program $100 million completed in 2025, with 3.5 million shares repurchased at an average price of $28.55 per share. An additional $100 million program was authorized by the Board.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
BRIUMVI U.S. net sales: Achieved $594 million in U.S. net sales for 2025, with a strong Q4 performance of $183 million, reflecting 92% year-over-year growth and 20% sequential growth from Q3.
6-year open-label extension data: Data from ULTIMATE I and II showed nearly 90% of patients were free from 24-week confirmed disability progression after 6 years of continuous treatment, with no new safety signals.
Phase III ENHANCE study: Enrollment completed for evaluating a single 600-mg dose consolidation of BRIUMVI infusions. Top-line data expected mid-2026, with a potential 2027 launch.
Subcutaneous BRIUMVI program: Phase III study is 75% enrolled, targeting top-line data later this year or early next year, with a potential 2028 launch. This program could nearly double the total addressable market.
Azer-cel CAR-T therapy: Being studied in progressive MS patients, with high demand for trial slots indicating unmet medical need. Updates expected later this year.
Anti-CD20 market positioning: BRIUMVI continues to gain share in the IV anti-CD20 segment, driven by proven efficacy, long-term safety, and operational efficiency. The subcutaneous program could expand the addressable market significantly.
Global revenue: Achieved $616 million in total global revenue for 2025, with $12.8 million from ex-U.S. commercialization and $9.4 million in royalty and other revenue.
Financial performance: Generated $123 million in operating income for 2025, with net income of $447.2 million, including a nonrecurring income tax benefit of $340 million.
Share repurchase program: Completed a $100 million share repurchase program and authorized an additional $100 million, reflecting confidence in long-term outlook.
Operating expenses: 2025 operating expenses totaled $328 million, in line with guidance, with additional investments in subcutaneous BRIUMVI manufacturing and commercial activities.
Partnership with Christina Applegate: Launched NextInMS.com, an educational platform for individuals with RMS, reflecting TG's commitment to supporting the MS community.
Capital allocation priorities: Focused on maximizing BRIUMVI's multibillion-dollar opportunity, pipeline expansion, share repurchases, and long-term returns.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially. These risks are detailed in their SEC filings.
Market Competition: BRIUMVI operates in a competitive IV anti-CD20 market. The company faces competitive pressures from other entrants in the market, which could impact its market share and growth trajectory.
Operational Costs: Incremental manufacturing and development costs related to subcutaneous BRIUMVI and commercial investments have driven operating expenses higher than initially guided.
Economic and Seasonal Variability: The company notes seasonal headwinds such as benefit reverifications and gross-to-net variability driven by deductible resets, which can influence the timing of net revenue early in the year.
Pipeline Development Risks: The success of the subcutaneous BRIUMVI program and other pipeline developments, such as Azer-cel, is uncertain and subject to clinical trial outcomes and regulatory approvals.
Financial Risks: The company has allocated significant resources to share repurchase programs and capital investments, which could pose risks if expected cash flow projections are not met.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company reaffirmed its full-year U.S. BRIUMVI net revenue guidance of $825 million to $850 million, with total global revenue expected to be $875 million to $900 million.
First Quarter 2026 Revenue Expectations: U.S. revenue is expected to grow sequentially over Q4 2025 levels to approximately $185 million to $190 million, even after accounting for typical seasonal headwinds. Ex-U.S. revenue is expected to be in the range of $5 million to $10 million for the first quarter.
Subcutaneous BRIUMVI Development: The company is developing a self-administered at-home subcutaneous BRIUMVI delivered via an auto-injector. The Phase III study is approximately 75% enrolled, with pivotal top-line data expected later this year or early next year. A potential launch is targeted for 2028.
Consolidated BRIUMVI Infusion Schedule: The Phase III ENHANCE study evaluating a single 600-milligram dose infusion schedule is complete, with top-line data expected midyear. A potential launch is targeted for 2027.
Expansion into Additional Autoimmune Indications: Plans are underway to explore BRIUMVI in additional autoimmune indications, including Myasthenia Gravis, with early Phase I study results already available.
Azer-cel Development: Azer-cel, an allogeneic anti-CD19 CAR-T therapy, is being studied in patients with progressive MS. Updates from this program are expected later this year.
Operating Expenses for 2026: Full-year operating expenses are expected to be approximately $350 million, excluding noncash compensation, plus $100 million in expenses related to subcutaneous BRIUMVI manufacturing and secondary manufacturer start-up activities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: TG Therapeutics completed its first $100 million share repurchase program and the Board authorized an additional $100 million last year. The company views its shares as significantly undervalued relative to the expected cash flow profile over the coming years. They are prepared to act accordingly, including adding leverage to reduce the share count. The company emphasizes that share purchases are aimed at creating long-term value rather than for optics.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you help us think about how the dynamics of subcutaneous uptake and self-administered first-line use fit together, and where you're currently seeing the strongest incremental momentum by site of care?
A:The company has been operating alongside Roche's new entry for several quarters and continues to see share gains in the IV segment. Growth is observed across private practice and academic centers, driven by clinical data, operational advantages like 1-hour infusion, and strong persistence. Enrollments are at their highest since launch, with strong demand and share gains across patient types and sites of care.
Q:Are you seeing any meaningful change in gross to net assumptions as growth evolves across channels, or does your prior framework still hold?
A:Gross to net can vary quarter-to-quarter, influenced by deductible resets and high utilization of co-pay programs in Q1. This is consistent with historical trends and does not represent a structural change. The full-year guidance reflects the net revenue profile for the year.
Q:Can you provide more detail on the proportion of new versus switch patients, revenue from long-term patients, and whether new patient starts are still growing or leveling off?
A:The company is seeing record new patient enrollments and growth in the IV segment. The business is becoming more predictable with more repeat patients as a larger part of the business. Persistence is strong, with patients staying on therapy for extended periods (up to week 96). Growth is expected in 2026, with meaningful contributions to guidance.
Q:How much conservatism is baked into the guidance, and what are the plans for commercializing subcutaneous BRIUMVI ex-U.S.?
A:The guidance is somewhat conservative, reflecting early-year dynamics. The company expects potential outperformance from new patient starts, share gains, and better persistence. Incremental investment for subcutaneous launch in the U.S. is minimal due to overlap with the current field force. Ex-U.S. commercialization will involve partners like Neurax.
Q:What is your perspective on the role of subcutaneous offerings versus IV, and how might the market evolve with new options?
A:The subcutaneous market has been stable at 35%-40%. New options could expand the market over time, with forces pushing towards subcutaneous at-home treatments. The company believes the market will grow with more energy and marketing in the space.
Q:Is there a need for a refocus of the sales force's goals this year, and what are the expense projections related to the DTC campaign?
A:The company continues to strategically expand its field force and does not see a need for new goals. The team is performing well with a pay-for-performance culture. Expense projections for the DTC campaign were not detailed, but the campaign is exceeding expectations in engagement metrics.
Q:When might we see subcutaneous bioequivalence data and earlier-stage program data?
A:Phase III subcutaneous data is expected later this year or early next year. Phase I bioequivalence data is nearly complete, and its presentation will depend on timing and conference schedules. Early-stage program data, such as for Myasthenia Gravis, is promising but lacks a specific timeline for presentation.
Q:What is the market potential for the ENHANCE trial launch, and are there any early metrics from the DTC campaign?
A:The ENHANCE trial, which eliminates the second dose, is expected to drive market share gains due to increased convenience. Early metrics from the DTC campaign, including website visits and engagement, have exceeded expectations.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on expense projections for the DTC campaign and the exact timeline for presenting early-stage program data, such as for Myasthenia Gravis.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Applegate MS
Applegate NextInMScom
Azer cel
BRIUMVI MS
BRIUMVI auto
BRIUMVI campaign
BRIUMVI confidence
BRIUMVI franchise
BRIUMVI hour
BRIUMVI infusion
BRIUMVI momentum
BRIUMVI outlook
BRIUMVI position
Bowl
Chief Commercial
Commercial Officer
Communications
IV segment
MS community
Phase III
Physicians
base
capital
cash flow
category
conversation life
depth
engagement
expansion
footprint
level
life MS
patient start
platform
relapse
schedule
space
subcu
value
year treatment
TGTX Transcript
TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call highlights a significant revenue increase of 45% YoY, indicating positive financial performance. However, the company's net loss and increased operating expenses raise concerns. Strategic execution and regulatory risks were noted, and management's unclear responses during the Q&A add uncertainty. The lack of discussion on strategic initiatives and shareholder returns further tempers optimism, resulting in a neutral sentiment.
TG Therapeutics, Inc. (TGTX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong financial performance with 20% sequential growth and a significant net income increase, even considering the nonrecurring tax benefit. The raised revenue guidance and successful share repurchase program further support a positive outlook. Although operating expenses exceeded guidance, the company's strategic investments are expected to pay off. The Q&A section highlights strong demand and market share gains, with conservative guidance suggesting potential upside. Overall, these factors indicate a positive sentiment and likely stock price increase in the short term.
TG Therapeutics, Inc. (TGTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
TGTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
